Loading
Not every BRAF mutation is the notorious one. The other 22% of BRAF-mutant bowel cancers occur in younger patients, on the left, and live five times longer than the V600E group.
A multicentre retrospective cohort study pooled patients with non-V600 BRAF mutations from next-generation sequencing databases at three large molecular genetics reference laboratories. Of 9,643 patients with metastatic colorectal cancer tested, 208 had non-V600 BRAF mutations, 2.2% of all patients and 22% of all BRAF mutations identified. Compared with V600E BRAF-mutant cancers, non-V600 cancers occurred in significantly younger patients (58 against 68 years), fewer female patients (46% against 65%), fewer high-grade tumours (13% against 64%) and fewer right-sided primaries (36% against 81%). Median overall survival was 60.7 months for non-V600 BRAF against 11.4 months for V600E and 43.0 months for BRAF wild-type disease, and in multivariable analysis non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio 0.18).
It stops a BRAF-mutant report being read as a death sentence, and it separates the class II and III mutations, which signal differently and are not covered by the encorafenib plus cetuximab label, from V600E.
Shares BEACON CRC, BRAF V600E (and V600K), Sidedness (left vs right colon), Encorafenib.
Shares BREAKWATER, BEACON CRC, Encorafenib, BRAF.
Shares Scott Kopetz, BREAKWATER, BEACON CRC, Encorafenib.
Shares BREAKWATER, BEACON CRC, Encorafenib, BRAF.
Shares BEACON CRC, BRAF V600E (and V600K), Encorafenib, BRAF.
Shares Encorafenib, BRAF, RAS / RAF / MEK / ERK (MAPK), Colorectal cancer.
Shares Scott Kopetz, BRAF V600E (and V600K), Encorafenib, MD Anderson Cancer Center.
Shares BRAF class II and class III mutations (non-V600), BRAF V600E (and V600K), BRAF.